Eckert & Ziegler Strahlen- und Medizintechnik AG (CH:EUZ)
:EUZ
EUZ Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strong Margins And ProfitabilitySustained high gross, operating and EBITDA margins indicate differentiated products and scale in radiopharmaceuticals. Such margin breadth supports durable earnings generation, reinvestment capacity and resilience to moderate volume swings over the next 2–6 months.
Conservative Balance Sheet And High ROELow leverage and strong returns on equity provide financial flexibility for capex, targeted investments or partnerships without stressing solvency. This capital conservatism reduces refinancing risk and supports durable strategic optionality in a regulated industry.
Structural Demand And Supply AdvantagesThe business supplies critical radioisotopes and services where reliability and compliance matter. Regulatory barriers and entrenched customer supply relationships create durable competitive advantages, supporting stable revenue streams and pricing power over medium term.
Bears Say
Weak Free Cash Flow ConversionFree cash flow covering only half of reported net income and showing a downtrend raises concern about earnings quality and internal funding capacity. Persistent weak conversion limits dividend, buyback or investment flexibility and increases reliance on working-capital or financing actions.
Profitability VolatilityA history of materially higher past net margins followed by normalization suggests sensitivity to product mix, pricing or cost swings. Such margin volatility complicates forward earnings predictability and planning for sustained reinvestment or shareholder returns.
Balance-sheet VariabilityShifts in total assets year-to-year indicate non-steady investment or working-capital patterns. This variability can translate into timing risk for cash flow and capital deployment, requiring closer monitoring of capex, inventory and receivables management.
Eckert & Ziegler Strahlen und Medizintechnik News
EUZ FAQ
What was Eckert & Ziegler Strahlen- und Medizintechnik AG’s price range in the past 12 months?
Currently, no data Available
What is Eckert & Ziegler Strahlen- und Medizintechnik AG’s market cap?
Eckert & Ziegler Strahlen- und Medizintechnik AG’s market cap is CHF886.73M.
When is Eckert & Ziegler Strahlen- und Medizintechnik AG’s upcoming earnings report date?
Eckert & Ziegler Strahlen- und Medizintechnik AG’s upcoming earnings report date is Aug 13, 2026 which is in 71 days.
How were Eckert & Ziegler Strahlen- und Medizintechnik AG’s earnings last quarter?
Eckert & Ziegler Strahlen- und Medizintechnik AG released its earnings results on May 12, 2026. The company reported CHF0.152 earnings per share for the quarter, beating the consensus estimate of N/A by CHF0.152.
Is Eckert & Ziegler Strahlen- und Medizintechnik AG overvalued?
According to Wall Street analysts Eckert & Ziegler Strahlen- und Medizintechnik AG’s price is currently Undervalued.
Does Eckert & Ziegler Strahlen- und Medizintechnik AG pay dividends?
Eckert & Ziegler Strahlen- und Medizintechnik AG does not currently pay dividends.
What is Eckert & Ziegler Strahlen- und Medizintechnik AG’s EPS estimate?
Eckert & Ziegler Strahlen- und Medizintechnik AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eckert & Ziegler Strahlen- und Medizintechnik AG have?
Currently, no data Available
What happened to Eckert & Ziegler Strahlen- und Medizintechnik AG’s price movement after its last earnings report?
Eckert & Ziegler Strahlen- und Medizintechnik AG reported an EPS of CHF0.152 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Eckert & Ziegler Strahlen- und Medizintechnik AG?
Currently, no hedge funds are holding shares in CH:EUZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eckert & Ziegler Strahlen und Medizintechnik Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF18.48 (― Downside)
CHF18.48 (― Downside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.45%
12-Months-Change
Fundamentals
Return on Equity
20.26%
Trailing 12-Months
Asset Growth
5.51%
Trailing 12-Months
Company Description
Eckert & Ziegler Strahlen- und Medizintechnik AG
Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates in two segments, Medical and Isotope Products. The Medical segment offers small radioactive implants for the treatment of prostate cancer seeds; and eye application based on ruthenium-106 or iodine-125 for treating uveal melanoma. This segment also provides radiopharmaceuticals, laboratory equipment, hot cells, and services for radiopharmaceuticals, as well as eye applicators and prostate implants. The Isotope Products segment manufactures and sells radiation sources for imaging, measurement technology, material analysis, quality assurance, and environmental monitoring. This segment also offers calibration sources for medical imaging systems, and homeland security and radiometric level measurement products. The company was founded in 1992 and is headquartered in Berlin, Germany.
EUZ Stock 12 Month Forecast
Average Price Target
CHF18.48
Gerresheimer
―
MeVis Medical Solutions
―
STRATEC Biomedical
―
Siemens Healthineers AG
―
MagForce AG
―
Options Prices
Currently, No data available
---